Literature DB >> 18555750

Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53.

Ji-Ching Lai1, Ya-Wen Cheng, Yih-Gang Goan, Jinghua Tsai Chang, Tzu-Chin Wu, Chih-Yi Chen, Huei Lee.   

Abstract

Methylation of the O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter is associated with G:C to A:T transitions in the p53 gene in various human cancers, including lung cancer. In tumors with p53 mutation, MGMT promoter methylation is more common in advanced tumors than in early tumors. However, in tumors with wild-type p53, MGMT promoter methylation is independent of tumor stage. To elucidate whether p53 participates in MGMT promoter methylation, we engineered three cell models: A549 cells with RNA interference (RNAi)-mediated knockdown of p53, and p53 null H1299 cells transfected with either wild-type p53 (WT-p53) or mutant-p53 (L194R, and R249S-p53). Knockdown of endogenous p53 increased MGMT promoter methylation in A549 cells, and transient expression of WT-p53 in p53 null H1299 cells diminished MGMT promoter methylation, whereas the MGMT promoter methylation status were unchanged by expression of mutant-p53. Previous work showed that p53 modulates DNA-methyltransferase 1 (DNMT1) expression; we additionally examined chromatin remodeling proteins expression levels of histone deacetylase 1 (HDAC1). We found that p53 knockdown elevated expression of both DNMT1 and HDAC1 in A549 cells. Conversely, expressing WT-p53 in p53 null H1299 cells reduced DNMT1 and HDAC1 expression, but the reduction of both proteins was not observed in expressing mutant-p53 H1299 cells. CHIP analysis further showed that DNMT1 and HDAC1 binding to the MGMT promoter was increased by MGMT promoter methylation and decreased by MGMT promoter demethylation. In conclusion, MGMT promoter methylation modulated by p53 status could partially promote p53 mutation occurrence in advanced lung tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555750     DOI: 10.1016/j.dnarep.2008.04.016

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  8 in total

Review 1.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

2.  Role of loss of o⁶-methylguanine dna methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression.

Authors:  Na-Hye Myong
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

Review 3.  Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools.

Authors:  Anthony E Pegg
Journal:  Chem Res Toxicol       Date:  2011-04-28       Impact factor: 3.739

4.  RAD51D protects against MLH1-dependent cytotoxic responses to O(6)-methylguanine.

Authors:  Preeti Rajesh; Changanamkandath Rajesh; Michael D Wyatt; Douglas L Pittman
Journal:  DNA Repair (Amst)       Date:  2010-02-04

5.  Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.

Authors:  Rita Arabsolghar; Tayebeh Azimi; Mozhgan Rasti
Journal:  Mol Biol Rep       Date:  2012-12-15       Impact factor: 2.316

6.  Gene Therapy for Human Lung Adenocarcinoma Using a Suicide Gene Driven by a Lung-Specific Promoter Delivered by JC Virus-Like Particles.

Authors:  Chun-Nun Chao; Mien-Chun Lin; Chiung-Yao Fang; Pei-Lain Chen; Deching Chang; Cheng-Huang Shen; Meilin Wang
Journal:  PLoS One       Date:  2016-06-20       Impact factor: 3.240

Review 7.  The significance of epigenetic alterations in lung carcinogenesis.

Authors:  Ewa Brzeziańska; Agata Dutkowska; Adam Antczak
Journal:  Mol Biol Rep       Date:  2012-10-20       Impact factor: 2.316

8.  Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.

Authors:  Xiao-Bing Jiang; Bin Hu; Dong-Sheng He; Zhi-Gang Mao; Xin Wang; Bing-Bing Song; Yong-Hong Zhu; Hai-Jun Wang
Journal:  BMC Cancer       Date:  2015-09-23       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.